<?xml version="1.0" encoding="UTF-8"?>
<p>The combination of lopinavir/ritonavir protease inhibitors (marketed as Kaletra for the treatment of HIV infection), with or without IFNÎ², is another viable candidate in the fight against SARS-CoV-2 (
 <xref rid="B54" ref-type="bibr">54</xref>). It is already included in the MIRACLE study against the MERS virus, and the first study in China against SARS-CoV-2 has been started. In addition, a team of experts from Wuhan (the city where the infection began) developed a best practice guide, following the management of a large number of patients. In addition to supportive treatment, the guide includes the use of lopinavir + ritonavir + IFN, which is, however, supported by only a low level of scientific certainty (the recommendation is based on use in SARS and MERS infections, related but not identical, to SARS-CoV-2) (
 <xref rid="B55" ref-type="bibr">55</xref>).
</p>
